A cewar Jabbar et al. Na Jami'ar Gothenburg a Sweden, ƙididdigar ƙirar ƙirar da aka yi niyya bisa dogaro da masu nazarin halittu uku kawai na ƙwanƙwasa za su iya ganowa da kimantawa sosai. yiwuwar pancreatic mafitsara tasowa cikin ciwon cizon sauro . Yana da kyau a gudanar da wasu nazarin don tabbatar da ko wannan hanyar gwaji na iya taimakawa wajen gano ciwon daji a cikin lokaci, nasarar shiga tsakani da kuma hana ciwon daji. (J Clin Oncol. Sigar kan layi Nuwamba 22, 2017)
Cystic lesions of the pancreas are very common in imaging, and about half are ciwon cizon sauro lesions. Therefore, accurate and specific diagnosis is essential for the correct treatment of patients. Unfortunately, the currently used diagnostic methods cannot effectively distinguish between pancreatic precancerous lesions and malignant pancreatic cystic lesions.
Masu binciken sun yi amfani da samfuran ruwa na ruwa wanda aka samo ta hanyar fakawa a karkashin jagorancin maganin gargajiya na zamani don nazarin. A cikin ƙungiyar gamayyar marasa lafiya 24, hanyar nazarin halittu mai gina jiki ta gano 8 masu nazarin halittun da zasu iya ba da bayani game da mummunan canji da canjin dysplasia / cutar kansa. Bayan haka, an yi nazarin kimantawa na 30 da aka yiwa lakabi da peptides da daidaitaccen aikin lura da yanayin kallo akan marasa lafiya 80 a cikin bayanan bayanan da marasa lafiya 68 a cikin tsarin tabbatarwa. Pointarshen binciken shine sakamakon binciken cututtukan cututtuka ko bin asibiti.
The results show that the best markers for malignant tumors may be a group of peptides derived from MUC-5AC and MUC-2. These markers can identify precancerous lesions / malignant lesions from benign lesions. The accuracy is as high as 97%. Compared with the cystic liquid carcinoembryonic antigen and cytological detection of these standard identification methods, the accuracy of these standard methods is 61% (95% CI 46% ~ 74%, P <0.001) and 84% (95% CI 71% ~ 92%, P = 0.02). MUC-5AC combined with prostate stem cell antigen can identify high-grade dysplasia or cancer, with an accuracy of 96%, can detect 95% of malignant lesions or severe dysplasia, and the detection rate of carcinoembryonic antigen and cytology 35% and 50% respectively (P <0.001, P = 0.003).
